<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672019</url>
  </required_header>
  <id_info>
    <org_study_id>18-366</org_study_id>
    <nct_id>NCT03672019</nct_id>
  </id_info>
  <brief_title>A Quality of Life Study in Patients Undergoing Percutaneous Biliary Drainage</brief_title>
  <official_title>Health-Related Quality of Life in Patients Undergoing Percutaneous Biliary Drainage For Malignant Biliary Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the participant's health-related quality of life
      before and after the biliary drainage procedure. The study will also help us learn whether
      having a drainage catheter or a stent placed during the procedure makes a difference in the
      participant's quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in the FACT-Hep scores</measure>
    <time_frame>baseline to week 4 post-procedure</time_frame>
    <description>The FACT-Hep minimum score is 0 and the maximum is 180.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Malignant Biliary Obstruction</condition>
  <arm_group>
    <arm_group_label>Patients Undergoing Percutaneous Biliary Drainage</arm_group_label>
    <description>Following Percutaneous Biliary Drainage (PBD), participants will complete Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>FACT-Hep</intervention_name>
    <description>Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).</description>
    <arm_group_label>Patients Undergoing Percutaneous Biliary Drainage</arm_group_label>
    <other_name>The Functional Assessment of Cancer Therapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential research subjects will be identified in the interventional radiology clinic or
        while admitted based on a request for a biliary drainage procedure from their primary
        oncologist or surgeon at MSK.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with known malignancy presenting for treatment of biliary obstruction

          -  Undergoing initial Interventional Radiology PBD procedure

          -  Fluent in English to enable instrument completion

          -  At least18 years of age

          -  Must be physically and mentally capable of completing instruments

          -  Must be able to comprehend and execute informed consent

        Exclusion Criteria:

          -  Patients will be excluded if:

               -  Indication for drainage is acute, symptomatic cholangitis requiring an emergent
                  procedure

               -  Previous PBD procedure

               -  Presence of an indwelling biliary stent

          -  Medical or psychiatric condition that, in the judgment of the consenting professional,
             prevents appropriate comprehension and execution of either the informed consent or the
             study instruments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piera Cote Robson, MSN, CNS, NP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piera Cote Robson, MSN, CNS, NP</last_name>
    <phone>212-639-7751</phone>
    <email>robsonp@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynn Brody, MD</last_name>
    <phone>212-639-2854</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Consent only)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piera Cote Robson, MSN, CNS, NP</last_name>
      <phone>212-639-7751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Consent only)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piera Cote Robson, MSN, CNS, NP</last_name>
      <phone>212-639-7751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (Consent only)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piera Cote Robson, MSN, CNS, NP</last_name>
      <phone>212-639-7751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (Consent only)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piera Cote Robson, MSN, CNS, NP</last_name>
      <phone>212-639-7751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piera Cote Robson, RN, BSN, NP</last_name>
      <phone>212-639-7751</phone>
    </contact>
    <contact_backup>
      <last_name>Lynn Brody, MD</last_name>
      <phone>212-639-2854</phone>
    </contact_backup>
    <investigator>
      <last_name>Piera Robson, RN, BSN, NP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Biliary Drainage</keyword>
  <keyword>Quality of life</keyword>
  <keyword>18-366</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

